^
Association details:
| Biomarker: | AR splice variant 7 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Thus AR-V7 may be a useful predictive biomarker in men with metastatic CRPC after progression on abiraterone or enzalutamide. These clinical experiences suggest that AR-V7 assays are promising predictors of abiraterone and enzalutamide resistance.
Source:
Title:
Prostate PMSABR Study
Excerpt:
...Progression-Free Survival`Time to progression`Overall survival`Local control rate of the SABR-treated oligometastasis at 6 months after SABR`Local control rate of the SABR-treated oligometastasis at 6 months after SABR based on the PERCIST criteria`QOL (EORTC QLQ-C30)`Time to next systemic treatment`The number of participants with treatment-related adverse event as assessed by CTCAE v4.0`The proportion of patients in both arms who have AR-V7 (CTCs)...
Trial ID:
Source:
Title:
Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA
Excerpt:
...Change in expression of androgen receptor abnormalities (e.g. ARV7, AR mutations) following abiraterone/enzalutamide treatment...
Trial ID:
More C2 evidence
Source:
Title:
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
Excerpt:
...Kaplan-Meier-like curves (likely adjusted for interval censoring) will be used to display the development of AR-V7 positivity. ...
Trial ID:
Source:
Title:
PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
Excerpt:
...To assess the prognostic value for overall survival of androgen receptor splicing variant 7 (AR-V7) and/or AR amplification in mCRPC patients...
Trial ID:
Source:
Title:
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
Excerpt:
...Changes in Quality of Life Assessment Scores, Assessed Using FACIT-Fatigue Scale and RANDSF-36 Surveys`Objective Response Rate to Enzalutamide in Patients With Measurable Disease on CT Scan`Response Rate With Dexamethasone by AR-V7 Status at Study Entry`Response Rate With Enzalutamide by AR-V7 Status at Study Entry`Time to PSA Progression, Based Upon PCWG2 Criteria, for Treatment With Dexamethasone`Time to Radiographic Progression for Treatment With Dexamethasone...
Trial ID:
Source:
Title:
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Excerpt:
...Correlate AR-V7 status in circulating tumor cells (positive versus negative) and PSA response decline > 50% after therapy with docetaxel`Correlate AR-V7 status in circulating tumor cells (positive versus negative) and PSA decline > 50% after therapy with enzalutamide`Correlate AR mutations (present versus absent) and PSA response decline > 50% after therapy with docetaxel.`...
Trial ID:
Source:
Title:
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Excerpt:
...Percentage of Participants With a >= 50% Decline in Prostate-specific Antigen (PSA) Value`Percentage of Participants With Tumor Protein 53 Gene (TP53) Copy Number Alterations and Mutations`Percentage of Participants With Phosphatase and Tensin Homologue Gene (PTEN) Copy Number Alterations and Mutations`Percentage of Participants With Retinoblastoma Gene (RB1) Copy Number Alterations and Mutations`Androgen Receptor (AR) Messenger RNA (mRNA) Expression`Androgen Receptor Variant 7 (AR-V7) Expression`Percentage of Participants With Androgen Receptor (AR) Copy Number Alterations and Mutations`Number of Participants With Protein Expression of AR`Androgen Receptor (AR) Activity Level...
Trial ID:
Source:
Title:
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
Excerpt:
...- Expression of AR-V7 is...
Trial ID:
Source:
Title:
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Excerpt:
...- Detectable AR-V7 from circulating tumors (CTCs)...
Trial ID:
Less C2 evidence
Source:
Title:
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Published date:
03/14/2019
Excerpt:
...Androgen receptor splice variant 7 (AR-V7)...We enrolled 118 men with mCRPC who were starting abiraterone or enzalutamide treatment. Detection of AR-V7 in CTCs by two blood-based assays is independently associated with shorter PFS and OS with abiraterone or enzalutamide…
DOI:
10.1200/JCO.18.01731
Trial ID:
Source:
Title:
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer
Excerpt:
Presence of an ARV7 variant was associated with primary resistance to enzalutamide (p = 0.018).
DOI:
10.1016/j.eururo.2014.05.005
Trial ID:
Source:
Title:
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
Excerpt:
Detection of AR-V7 in circulating tumor cells from patients with castration-resistant prostate cancer may be associated with resistance to enzalutamide and abiraterone.
DOI:
10.1056/NEJMoa1315815
